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Abstract
Background: The aim of this study was to characterize the hCMEC/D3 cell line, an in vitro model of the human
Blood Brain Barrier (BBB) for the expression of brain endothelial specific claudins-3 and -12.
Findings: hCMEC/D3 cells express claudins-3 and -12. Claudin-3 is distinctly localized to the TJ whereas claudin -12
is observed in the perinuclear region and completely absent from TJs. We show that the expression of both
proteins is lost in cell passage numbers where the BBB properties are no longer fully conserved. Expression and
localization of claudin-3 is not modulated by simvastatin shown to improve barrier function in vitro and also
recommended for routine hCMEC/D3 culture.
Conclusions: These results support conservation of claudin-3 and -12 expression in the hCMEC/D3 cell line and
make claudin-3 a potential marker for BBB characteristics in vitro.
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Background
Members of the claudin superfamily are important pro-
tein constituents of tight junctions (TJs) in polarized
epithelial and endothelial monolayers and play an
important role in maintaining the paracellular barrier.
At the blood brain barrier (BBB), claudins-1,-3, -5 and
-12 have been shown to participate in the formation of
TJs between brain microvascular endothelial cells in
vivo [1-4]. Of these members, there has been a particu-
lar interest in claudin-5, as mice deficient for this pro-
tein showed size dependent transport restriction for
molecules smaller than 800 Da. Claudin-12 is highly
expressed at the TJs in murine development [3]. Clau-
din-3 expression in primary human, rat and murine
brain endothelial TJs is no longer of debate since anti-
bodies that are not cross-reactive to claudin-1 have been
generated [5-7]. The loss of claudin-3 from the TJs in
experimental allergic encephalomyelitis (EAE) demon-
strates that it may be important for determining perme-
ability in pathological conditions [4].
The hCMEC/D3 cell line is the best-characterized in
vitro model system of the human blood brain barrier.
The cells express endothelial specific and TJ markers
including claudins-1 and -5 [8,9]. The aim of the present
study was to establish the protein expression and locali-
zation pattern of the other brain endothelial specific
claudins-3 and -12 in the hCMEC/D3 cell line.
Methods
Cell culture
Simvastatin (Sigma) was reconstituted as described [10].
hCMEC/D3 cells were cultured as described [9]. Primary
endothelial cells (Cell Systems GmbH, Troisdorf, Ger-
many) were cultured according to instructions. MCF7
human breast adenocarcinoma, MDCK-2 canine kidney,
MEF1, Pea-13 and NIH-3T3 mouse fibroblast and U87
human glioblastoma cell lines were from American
Type Culture Collection (LGC Standards GmbH, Wesel,
Germany).
Western blot analysis
Protein concentration of whole cell lysates generated in
RIPA buffer were estimated (DC protein assay, Thermo
Scientific, Bonn, Germany) and 20 μg of denatured
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lysates resolved on NuPAGE gels (Invitrogen, Darm-
stadt, Germany) were transferred onto nitrocellulose
membranes (Invitrogen). Blocked membranes were incu-
bated overnight with 1.5 μg/ml of Claudin-3 (Invitrogen)
or 1 μg/ml claudin-12 (R&D Systems, Wiesbaden, Ger-
many) antibodies. Membranes were incubated with
HRP-conjugated IgG antibodies (Cell Signaling Technol-
ogy, Frankfurt, Germany) for 1 h at RT and developed
using Lumilight Plus detection reagents (Roche, Man-
nheim, Germany) and films exposed to the signal were
developed with an X-Omat 1000 automatic processor
(Kodak, Stuttgart, Germany).
Immunocytochemistry
Coverslip cultures of hCMEC/D3 or MDCK cells were
treated as described [9] and immunostained with 1.5 μg/
ml of claudin-3 or 5 μg/ml claudin-12 antibodies fol-
lowed by incubation with 10 μg/ml isotype-specific IgG
conjugated to Alexa Flour® 488 (Invitrogen). Coverslips
were mounted in UltraCruz mounting medium (Santa
Cruz, Heidelberg, Germany) and images obtained with a
Leica florescence microscope were processed using
MetaMorph software (Molecular Devices, Biberach, Ger-
many). Matched isotypes of the primary antibodies
served as negative controls.
Results
Claudin-3 and -12 are expressed but only claudin-3 is
localized at the TJs in the hCMEC/D3 cell line
We compared the expression of claudin-3 and claudin-
12 in hCMEC/D3 cells to primary human brain
endothelium and other non-endothelial based cell lines.
Under reducing conditions (Figure 1A), a ~23 kDa pro-
tein band corresponding to the size of claudin-3 was
observed in endothelial and epithelial cells (lanes, 1, 2,
3, 5, and 9). Claudin-3 levels are comparable between
primary brain endothelium (PHB, lane 1) and trans-
formed (hCMEC/D3, lane 3). Claudin-3 is strongly
expressed in epithelium where protein levels in MCF7
(lane 5) and MDCK cells (lane 9) are higher than that
observed in the brain endothelial cells (lanes 1, 3). Inter-
estingly, we see a loss of the claudin-3 protein in
hCMEC/D3 cells from passage 31 (lane 2) compared to
cells derived from passage 26 (lane 3).
Claudin-12 is a 27 kDa protein. Like other claudins, it is
regulated by post-translational modifications, a possible
reason for the higher molecular weight band observed. It
is expressed in primary and transformed brain endothe-
lium (Figure 1A, lanes 1, 2 and 3). The decrease in protein
levels with increase in passage number also appears to be
consistent for the claudin-12 protein (lanes 2 and 3). Clau-
din-12 is present in MDCK (lane 9) cells. Surprisingly it is
seen in the Pea-13 (lane 8) cells even though it is absent
from its parent line, MEF-1 (lane 7).
We proceeded to check the localization of the
expressed claudin-3 and claudin-12 proteins in the
hCMEC/D3 cell line (Figure 1B-E). Claudin-3 shows a
distinct localization at the tight junctions (Figure 1B)
also seen in the MDCK cells (Figure 1C). However, we
did not detect claudin-12 at the TJ in the hCMEC/D3
cells but observed immunoreactivity reminiscent of a
protein associated with the ER network (Figure 1D). We
checked if the antibody can detect protein at the TJ and
indeed the protein is observed at cell-cell borders in the
MDCK cells using this antibody (Figure 1E).
No modulation of claudin-3 protein expression and its
localization by simvastatin
Simvastatin, a member of the statin family, has been
proposed to positively modulate the poor TEER and
increased paracellular permeability inherent to the
hCMEC/D3 culture [11]. We investigated if simvastatin
improves the barrier properties by up-regulating expres-
sion or localization of claudin-3. Confluent or rested
hCMEC/D3 cells were cultured with or without 1 nM
simvastatin for 12 h (Figure 2). Western blot analysis
(Figure 2A) shows constant levels of claudin-3 protein
between the different conditions. While simvastatin
treatment does not appear to change claudin-3 localiza-
tion, rested cultures show a slightly more irregular stain-
ing pattern. (Figure 2B, C).
Discussion
The aim of this study was to characterize claudins-3 and
-12 inhCMEC/D3 cells. Our data support the following
conclusions:
1. Expression of claudins-3 and -12, but only clau-
din-3 is localized to the tight junction (Figures 1 and
2).
2. Common feature of claudins-3 and -12 is their
loss in higher passage numbers (Figure 1).
3. Simvastatin improvement of the monolayer integ-
rity is not mediated via increase in the expression or
localization of claudin-3.
We detected claudin-12 protein in primary and trans-
formed brain endothelium, but not at the TJ. In murine
development, claudin-12 is predominantly seen at the
TJs [4], while data on adult brain are only available at
the mRNA level: findings by Belanger et al. support
claudin-12 as a marker for metabolic disturbances
affecting brain function in the adult [12]. In an immor-
talized murine cell culture model, only claudin-12
mRNA levels were down-regulated under conditions
mimicking hyperammonemia. Taken together, it cannot
be excluded that claudin-12 exists as an intracellular
protein in the adult brain serving an as yet unknown
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Figure 1 Claudin-3 and Claudin-12 expression in hCMEC/D3 cells. A: Immunoblots showing claudin-3 (Cld 3, upper panel) and claudin-12
(Cld 12, lower panel) expression in whole cell lysates derived from primary human brain (lane 1, PHB) and hCMEC/D3 endothelial cells (lanes -2,
D3 p31 and -3, D3 p26) in addition to glioblastoma cells (lane 4, U87) or cells of fibroblast origin (lanes-6, MEF1; -7, Pea-13; -8, NIH 3T3), epithelial
(lanes -5, MCF-7 and -9, MDCK) origin. B-E: hCMEC/D3 cells (B, D) grown to confluence and further rested for 48 h or confluent cultures of MDCK
cells (C, E) were stained with antibodies to claudin-3 (B, C) or claudin-12 (D, E). Isotype matched antibodies did not stain cells (data not shown).
Scale bar = 25 μm.
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function, or its localization to the TJ in vitro might
require exquisite signaling input from other members of
the neurovascular unit like pericytes and astrocytes. We
did not test the hCMEC/D3 cells in co-culture with
astrocytes as they are not responsive to glial cell condi-
tioning in our experimental set-up.
So far, data on claudin-3 expression in immortalized
human brain endothelium is supported by data from
iHBMEC, an immortalized human brain endothelial cell
line [13]. The loss of the protein from tight junctions in
experimental EAE demonstrates its importance for
determining permeability in pathological conditions [4].
Figure 2 Influence of simvastatin on hCMEC/D3 confluent and rested monolayers. hCMEC/D3 cells were grown to confluence or further
rested for 48 h in medium lacking growth factors. In addition, confluent or rested cultures were incubated with 1 nM Simvastatin overnight at
37°C. A: Immunoblot showing claudin-3 expression under indicated conditions. B-E: Immunolocalization of claudin-3 in confluent (B,C) or rested
(D,E) cells in the presence (B,D) or absence (C,E) of simvastatin. Cells were immunostained with an antibody to the claudin-3 protein and
visualized with goat anti-rabbit IgG conjugated to Alexa Fluor® 488. Scale bar = 25 μm.
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In hCMEC/D3 cells, claudin-3 is observed as a combina-
tion of continuous lines and a serrated pattern at the
tight junctions, depending on culture conditions. The
protein is not detected in cells that no longer exhibit
the full complement of BBB properties in culture: TEER
values of hCMEC/D3 cells at early passages are in the
range of 35-40 ohm/cm2, while in p31 cells, the TEER
falls to 20-22 ohm/cm2. This supports the finding of
Wolburg et al. whose data identify claudin-3 as the pri-
mary marker for detecting loss in BBB integrity in vivo
[4]. Ifergan et al. observed that simvastatin improved
barrier properties of brain endothelial monolayers with-
out affecting expression or localization of occludin, ZO-
1, -2, VE-cadherin and JAM-1 proteins [10]. Claudin-3
protein expression or localization is also not modified
by addition of simvastatin to the culture medium. Clau-
dins-1 and-5 remain to be investigated for the effects of
simvastatin.
In conclusion, we present data confirming the expres-
sion of claudins-3 and-12 in the hCMEC/D3 cell line.
Claudin-3 is a possible marker for hCMEC/D3 mono-
layer integrity in studies investigating modulation of
BBB in vitro under pathological conditions. Further
work to identify the function of claudin-12 in the adult
brain and its binding partners remains to be
investigated.
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